ArticleComputational and structural biotechnology journal2021
A murine model to study the gut bacteria parameters during complex antibiotics like cefotaxime and ceftriaxone treatment.
Article in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 31 citations in OpenAlex.
- Persistent gut microbiota dysbiosis and metabolic remodeling after ceftriaxone exposure in mice: a cross-study re-analysis.Frontiers in cellular and infection microbiology · 2026Article
- Evaluating Effects of Antibiotics Across Preclinical Models of the Human Gastrointestinal Microbiota.MicrobiologyOpen · 2025Article
- Ceftriaxone alters the gut microbiome composition and reduces alcohol intake in male and female Sprague-Dawley rats.Alcohol (Fayetteville, N.Y.) · 2024Article
- Short-term exposure to antibiotics begets long-term disturbance in gut microbial metabolism and molecular ecological networks.Microbiome · 2024Article
- The Effects of Ceftriaxone on Glutamate Transporter Expression and the Gut Microbiome: Implications for a Role of Antibiotic-Induced Dysbiosis in Mediating Drug Seeking and Relapse.Gut microbes reports · 2024Article
- Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-ResistantFrontiers in microbiology · 2022Article
- Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe globally increasing resistance due to extended-spectrum beta-lactamase producing
methodsSWISS mice were treated either with ceftriaxone or with cefotaxime or with NaCl 0.9% as a control group from day 1 to day 5. We performed a gavage at day 4 with a
resultsMice treated with ceftriaxone were more colonized than mice treated with cefotaxime after gavage (p-value = 0.008; Kruskal-Wallis test). Ceftriaxone and cefotaxime were both excreted in large quantity in gut lumen but they drove architecture of the gut microbiota in different trajectories. Highest levels of colonization were associated with particular microbiota composition using principal coordinate analysis (PCoA) which were more often achieved in ceftriaxone-treated mice and which were preceded by highest fecal antibiotics concentrations in both cefotaxime or ceftriaxone groups. Using LEfSe, we found that twelve taxa were significantly different between cefotaxime and ceftriaxone-treated mice. Using SplinectomeR, we found that relative abundances of
conclusionCeftriaxone selects a particular microbial community and its substitution for cefotaxime could prevent the selection of extended-spectrum beta-lactamase producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.